Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Fibroblast Activating Protein Inhibitor (FAPI) -Mediated 18F Targeted to Evaluate Inflammation and Fibrosis in Renal Diseases

NCT05752097 is registered in ClinicalTrials.gov with Sichuan Provincial People's Hospital as lead sponsor.

NCT NCT05752097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05752097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Fibroblast Activating Protein Inhibitor (FAPI) -Mediated 18F Targeted to Evaluate Inflammation and Fibrosis in Renal Diseases
Lead sponsor
Sichuan Provincial People's Hospital
Phase
Observational
Overall status
Unknown status
Start date
February 1, 2023
Completion date
November 30, 2024
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

18f-fapi pet/ct examination, renal puncture biopsy